Catalent has announced that it will acquire Juniper Pharma Services (formerly Molecular Profiles) along with its parent company Juniper Pharmaceuticals. Catalent will pay $11.50 per share to acquire all of Juniper Pharmaceuticals’ stock.
Juniper Pharmaceuticals acquired CDMO Molecular Profiles in 2015 and changed its name to Juniper Pharma Services. Juniper has offered a wide range of services, including development and clinical trials manufacturing of dry powder inhalation formulations, at its Nottingham, UK facility.
In the announcement, Catalent, which has an Inhalation Center of Excellence located in the US, emphasized Juniper’s oral dosage capabilities, and said that the UK facility “will complement Catalent’s multi-site oral manufacturing network to provide pharmaceutical innovators with a comprehensive solution to accelerate their drug development processes.” The company did not say whether it would continue to offer inhalation product services in Nottingham.
Catalent President of Oral Drug Delivery Jonathan Arnold said, “Juniper’s proven solutions and capabilities will further support Catalent’s strategic goal to be the most comprehensive partner for pharmaceutical innovators. Juniper’s scientific expertise in early-phase product development and supply will help our customers unlock the full potential of their molecules and provide better treatments to patients, faster.”
Read the Catalent press release.
